PTCHF · PureTech Health plc
$1.57
At close · Aug 6
Market Cap
$380.95M
Shares
243.42M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.57
Open$1.55
Day$1.55–1.57
52W close$1.53–1.92
Avg vol 30d38K
Short int68K · 0.0% float · 203.4d
Short vol73%
Last earningsApr 29, 2026
DataJan 2020–Aug 2026
Up next
Next earnings call
Dec 28, 2026
Est · unconfirmed
· in 19 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−28%
below
Price vs 50-day avg
−7%
below
RSI (14)
45
neutral
MACD trend
Negative
52-week position
9%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−10%
trailing
6-month return
−46%
trailing
YTD return
−8%
this year
Relative strength
−59%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.03% of float · ▲ +28.5% MoM · 203.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
5 holders — mid 3-yr range
Squeeze score
48
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
87%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the Earnings Call filed Jun 30, 2024
PureTech level cash, cash equivalents, and short-term investment
· end of the year
$330M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−28%
Bearish
Price vs 50-day avg
−7%
Bearish
RSI (14)
45
Neutral
MACD trend
Negative
Bearish
52-week position
9%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.03% of float · ▲ +28.5% MoM · 203.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
5 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $2 · 9%
Range high $2
vs 200-day avg -28%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PTCHF
this stock
PureTech Health plc
|
$380.95M | -8.2% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
5
- % held
- 0.1%
- Net QoQ
- +44.6K sh
- Top holder
- Pentwater Capital Managem…
Held
Float
Short & Settlement
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PTCHF | -16.0% | -9.5% | -46.0% | +2.3% | -8.2% |
| SPY | +3.6% | +2.2% | +12.8% | +2.9% | +12.7% |
| vs SPY | -19.6% | -11.8% | -58.8% | -0.6% | -20.9% |